Diabetic Retinopathy

  • Alexandre A. C. M. Ventura
  • Hajir Dadgostar
  • Merhan Taban


Diabetic retinopathy (DR) is a chronic microvascular complication. It is characterized by progressive changes in the retinal microvasculature leading to areas of non-perfusion retina, increased vascular permeability, and intraocular pathological proliferation of retinal vessels. Complications associated with increased vascular permeability, called macular edema, and uncontrolled neovascularization, named proliferative diabetic retinopathy (PDR), can result in serious and permanent vision loss [1–4].


Optical Coherence Tomography Diabetic Retinopathy Macular Edema Fluorescein Angiography Proliferative Diabetic Retinopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ali MK, McKeever Bullard K, Imperatore G, et al. Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes–National Health and Nutrition Examination Survey, United States, 2007–2010. MMWR Morb Mortal Wkly Rep. 2012;61 Suppl:32–7.PubMedGoogle Scholar
  2. 2.
    Saaddine JB, Honeycutt AA, Narayan KM, et al. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophthalmol. 2008;126(12): 1740–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304(6):649–56.PubMedCrossRefGoogle Scholar
  4. 4.
    Crawford TN, Alfaro 3rd DV, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev. 2009;5(1):8–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113(10):1706–12.PubMedCrossRefGoogle Scholar
  6. 6.
    Frampton JE. Ranibizumab: in diabetic macular oedema. Drugs. 2012;72(4):509–23.PubMedCrossRefGoogle Scholar
  7. 7.
    Kumar B, Gupta SK, Saxena R, Srivastava S. Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med. 2012;58(2):132–9.PubMedGoogle Scholar
  8. 8.
    Lang GE. Diabetic macular edema. Ophthalmologica. 2012;227 Suppl 1:21–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang H, Sun X, Liu K, Xu X. Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Curr Eye Res. 2012;37(8):661–70.PubMedCrossRefGoogle Scholar
  10. 10.
    Klein R, Klein BE, Moss SE, et al. Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol. 1984;119(1):54–61.PubMedGoogle Scholar
  11. 11.
    Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102(4):527–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4):520–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464–74.PubMedGoogle Scholar
  14. 14.
    Grimsby JL, Porneala BC, Vassy JL, et al. Race-ethnic differences in the association of genetic loci with HbA1c levels and mortality in U.S. adults: the third National Health and Nutrition Examination Survey (NHANES III). BMC Med Genet. 2012;13:30.PubMedCrossRefGoogle Scholar
  15. 15.
    Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–51.PubMedGoogle Scholar
  16. 16.
    Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.PubMedCrossRefGoogle Scholar
  17. 17.
    The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes. 1986;35(5):530–45.CrossRefGoogle Scholar
  18. 18.
    Kahn HA, Hiller R. Blindness caused by diabetic retinopathy. Am J Ophthalmol. 1974;78(1):58–67.PubMedGoogle Scholar
  19. 19.
    Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102(1):7–16.PubMedCrossRefGoogle Scholar
  20. 20.
    Palmberg PF. Diabetic retinopathy. Diabetes. 1977; 26(7):703–9.PubMedCrossRefGoogle Scholar
  21. 21.
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977–86.Google Scholar
  22. 22.
    Javitt JC, Aiello LP, Bassi LJ, et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. American Academy of Ophthalmology. Ophthalmology. 1991;98(10):1565–73. discussion 74.PubMedGoogle Scholar
  23. 23.
    Javitt JC, Aiello LP, Chiang Y, et al. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care. 1994;17(8):909–17.PubMedCrossRefGoogle Scholar
  24. 24.
    Javitt JC, Canner JK, Sommer A. Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. Ophthalmology. 1989;96(2):255–64.PubMedGoogle Scholar
  25. 25.
    The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44(8):968–83.Google Scholar
  26. 26.
    Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 1996;276(17):1409–15.Google Scholar
  27. 27.
    Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287(19):2563–9.Google Scholar
  28. 28.
    Barr CC. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N. Engl. J. Med 342:381–9, 2000. Surv Ophthalmol. 2001;45(5):459–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Yam JC, Kwok AK. Update on the treatment of diabetic retinopathy. Hong Kong Med J. 2007;13(1): 46–60.PubMedGoogle Scholar
  30. 30.
    Fong DS. Changing times for the management of diabetic retinopathy. Surv Ophthalmol. 2002;47 Suppl 2:S238–45.PubMedCrossRefGoogle Scholar
  31. 31.
    Ferris 3rd FL, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med. 1999;341(9): 667–78.PubMedCrossRefGoogle Scholar
  32. 32.
    Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003;136(1):122–35.PubMedCrossRefGoogle Scholar
  33. 33.
    Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes Care. 2003;26(1):226–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care. 2004;27 Suppl 1:S84–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Bragge P, Gruen RL, Chau M, et al. Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol. 2011;129(4):435–44.PubMedCrossRefGoogle Scholar
  36. 36.
    Bernardes R, Serranho P, Lobo C. Digital ocular fundus imaging: a review. Ophthalmologica. 2011;226(4): 161–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Hannouche RZ, Avila MP. Detection of diabetic foveal edema with biomicroscopy, fluorescein angiography and optical coherence tomography. Arq Bras Oftalmol. 2008;71(5):759–63.PubMedCrossRefGoogle Scholar
  38. 38.
    Wessing A. Diabetic retinopathy: update on diagnosis and treatment. Nephrol Dial Transplant. 1997;12(9): 2013–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981;88(7):583–600.Google Scholar
  40. 40.
    Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology 1985;92(4): 492–502.Google Scholar
  41. 41.
    Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5 Suppl):766–85.Google Scholar
  42. 42.
    Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995;113(9):1144–55.Google Scholar
  43. 43.
    The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 1995;113(1): 36–51.Google Scholar
  44. 44.
    Jeganathan VS. Novel pharmacotherapies for diabetic retinopathy: current and future perspectives. Curr Pharm Biotechnol. 2011;12(3):336.PubMedCrossRefGoogle Scholar
  45. 45.
    Kozak I, Oster SF, Cortes MA, et al. Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS. Ophthalmology. 2011;118(6):1119–24.PubMedCrossRefGoogle Scholar
  46. 46.
    Nagpal M, Marlecha S, Nagpal K. Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser. Retina. 2010;30(3):452–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):e1–15. 1695.PubMedCrossRefGoogle Scholar
  48. 48.
    Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000; 23(4):504–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Heier JS, Brown DM, Chong V, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology. 2012; 119(12):2537–48.PubMedCrossRefGoogle Scholar
  50. 50.
    Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.PubMedCrossRefGoogle Scholar
  51. 51.
    Sfikakis PP, Markomichelakis N, Theodossiadis GP, et al. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care. 2005;28(2):445–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Tsilimbaris MK, Panagiotoglou TD, Charisis SK, et al. The use of intravitreal etanercept in diabetic macular oedema. Semin Ophthalmol. 2007;22(2):75–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Alexandre A. C. M. Ventura
    • 1
  • Hajir Dadgostar
    • 2
  • Merhan Taban
    • 3
  1. 1.Retina DepartmentHospital de Olhos Santa LuziaRecifeBrazil
  2. 2.OphthalmologyValley Retina Associates Medical GroupEncinoUSA
  3. 3.OphthalmologyRetina Macula InstituteTorranceUSA

Personalised recommendations